ScreenerHero

TAKTakeda Pharmaceutical Co. Ltd.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · takeda.com
18.18USDMkt Cap: 58.06B $P/E: —

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare d…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8
HIK
Hikma Pharmaceuticals PLC
$4.35BUSDP/E 12.7

Key Statistics

Company
Market Cap58.06B $
Enterprise Value5.13T $
Revenue (TTM)4.62T $
Gross Profit2.93T $
Net Income (TTM)-152.39B $
Revenue/Share1462.74 USD
Last Price18.18 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees47.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINJP3463000004
Valuation
P/E (Trailing)—
P/E (Forward)34.21
PEG0.42
EV/EBITDA4.11
EV/Revenue1.11
P/S0.01
P/B1.26
EPS (TTM)-0.32
EPS (Forward)0.53
52W Range
18.0861% of range18.25
52W High18.25 USD
52W Low18.08 USD
Profitability
Gross Margin65.12%
Oper. Margin16.45%
EBITDA Margin27.05%
Profit Margin-3.38%
ROE-2.05%
ROA-0.98%
Growth
Revenue Growth10.20%
Earnings Growth-9.80%
Cash Flow & Leverage
Operating CF1.04T $
CapEx (TTM)414.66B $
FCF Margin11.72%
FCF Yield932.59%
Net Debt5.08T $
Net Debt/EBITDA4.06
Balance Sheet
Debt/Equity0.66
Current Ratio1.14
Quick Ratio0.51
Book Value/Sh14.36 USD
Cash/Share145.85 USD
Dividends
Fwd Div Rate0.6200 USD
Trail. Div Rate200.00 USD
Div. Yield3.36%
5Y Avg Yield4.53%
Payout Ratio80.03%
Ex-Div DateMar 31, 2026
Pay DateJul 6, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)22.00 USD
Upside (mean)+21.0%
Target Range21.00 USD – 23.07 USD
$21.00+21.0% to mean$23.07
# Analysts3
Ownership
Shares Out.3.19B
Float3.16B
Insiders0.06%
Institutions3.30%
Short Interest
Short Ratio0.8d
Short % Float0.09%
Short % Out.0.09%
Shares Short2.87M
Short (prev mo.)5.26M
Technical
SMA 5016.68 (+9.0%)
SMA 20016.50 (+10.2%)
Beta0.10
S&P 52W Chg21.00%
Avg Vol (30d)1.39M
Avg Vol (10d)3.17M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—